Futures
Access hundreds of perpetual contracts
TradFi
Gold
One platform for global traditional assets
Options
Hot
Trade European-style vanilla options
Unified Account
Maximize your capital efficiency
Demo Trading
Introduction to Futures Trading
Learn the basics of futures trading
Futures Events
Join events to earn rewards
Demo Trading
Use virtual funds to practice risk-free trading
Launch
CandyDrop
Collect candies to earn airdrops
Launchpool
Quick staking, earn potential new tokens
HODLer Airdrop
Hold GT and get massive airdrops for free
Pre-IPOs
Unlock full access to global stock IPOs
Alpha Points
Trade on-chain assets and earn airdrops
Futures Points
Earn futures points and claim airdrop rewards
Pharvaris Moves Closer To New Preventive Treatment For Rare Swelling Disorder
Pharvaris (NASDAQ: PHVS) has completed enrollment for its CHAPTER 3 study of deucrictibant XR for hereditary angioedema (HAE). If the Q3 2026 data is positive, it could position Pharvaris as a comprehensive HAE treatment provider, according to Guggenheim Securities. Analyst Debjit Chattopadhyay maintains a Buy rating and $39 price target, citing a 70% probability of success and potential for a 30% upside if the drug significantly reduces monthly HAE attacks.